BETR-001's cluster headache program faces a measurement gap most CNS trials carry: the distance between patient-reported attack frequency and what's clinically happening between attacks. Videra Health captures the high-resolution behavioral data that makes the efficacy case to FDA and the value case to payers.
See how we'd observe BETR-001BetterLife's BOL-148 program for cluster headache — non-hallucinogenic 5-HT2A modulation in a high-need, underserved patient population.
BETR-001 is BetterLife's BOL-148 program targeting cluster headache — one of the most painful conditions in medicine, with limited approved treatment options and a small but high-need patient population.
The 5-HT2A mechanism without psychedelic effects is the commercial story. The measurement question — how do you prove efficacy in attacks that come in clusters and disappear in remission — is the trial design story.
Most cluster headache trials rely on patient-reported attack frequency. That data captures the events, but not the inter-attack burden, the anticipatory distress, the recovery patterns. Continuous voice and video monitoring across attack and remission periods generates the high-resolution data that makes the case to both FDA and payers.
The cluster headache market is small but high-need. Well-validated outcomes data is the difference between a niche launch and a foundational franchise.
BetterLife Pharma's non-hallucinogenic 5-HT2A program for cluster headache.
Four observation gaps separate 'fewer attacks' from a foundational cluster headache franchise.
Patient-reported attack frequency captures the events but not the anticipatory anxiety, the sleep disruption, the functional impairment. Continuous behavioral monitoring across attack and remission periods captures all of it.
Vocal stress markers, facial pain expression, and linguistic content during and after attacks generate the objective severity data that strengthens efficacy claims and payer access conversations.
BETR-001's value proposition includes faster between-attack recovery. Continuous behavioral capture surfaces that recovery curve in trial data and post-launch evidence.
Cluster headache is a high-need but small market. The difference between 'covered' and 'not covered' often comes down to data depth. Videra delivers it.
Our platform pairs in-clinic AI hardware with multimodal behavioral analytics and a custom algorithm engine, already proven in TDScreen and Check on Mom. Here's how each maps to BETR-001.
A clinical-grade camera and directional audio rig that drops into any BETR-001 site in minutes. Every patient assessment captured consistently — the baseline for objective attack severity and recovery measurement.
Multimodal analysis of voice, video, and language across attacks and remission periods, captured remotely between clinic visits. The data depth a small but high-need market requires.
For BETR-001, that means a proprietary attack severity and inter-attack burden index — capturing the full disease burden that drives both regulatory approval and payer access.
AI-powered tardive dyskinesia screening built on the AIMS standard. AUC 0.89 vs. trained raters, peer-reviewed in J Clin Psychiatry.
Conversational AI + video screener for postpartum depression. Used in real homes, on real devices, validated against clinical frameworks.
Multimodal AI model trained on BETR-001 Phase 2 data, capturing attack severity, recovery trajectory, and inter-attack burden in a way attack diaries cannot.
Your BETR-001 development strategy, mapped to Videra capabilities in production.
Videra's network isn't our customer base. It's the living dataset that powers every algorithm we build. For BetterLife Pharma, that means real clinical depth and peer-reviewed validation.
We'd welcome a 30-minute session to walk BetterLife Pharma through a tailored, protocol-by-protocol proposal for BETR-001's cluster headache program.